Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Atenolol Zeneca · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.) |
| 2 | ACTIVE_COMPARATOR | Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical) |
| Name | Type | Description |
|---|---|---|
| Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical) | DRUG | - |
| Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.) | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.
Atenolol Zeneca is an investigational small molecule being studied in angina, a cardiovascular condition. It is a 100 mg tablet formulation. Development is at Phase 1, so it is not an approved product and remains in clinical development.
Atenolol Zeneca targets ADRB1, the beta-1 adrenergic receptor, and acts as an antagonist at that receptor. Antagonist activity at ADRB1 is the mechanism described for this asset in its cardiovascular development program for angina.
Atenolol Zeneca is being developed by Novartis AG, which trades under the ticker NVS. The asset is a small molecule tablet formulation in the cardiovascular therapeutic area, with development currently at the Phase 1 stage.
Atenolol Zeneca is in Phase 1 development. It is an investigational asset and is not approved. One Phase 1 trial has been completed, and no trials are currently active, so clinical work to date has been limited to early-stage study.
Atenolol Zeneca has been studied in one completed Phase 1 trial, NCT00946725, titled to demonstrate the relative bioavailability of atenolol tablets, 100 mg. That trial enrolled 28 healthy male volunteers aged 18 years and older and used a randomized, active-controlled design without double blinding.